In the original published version of the article,1 Prof. Peggs was inadvertently omitted from the list of authors. His name has been added in recognition of his contribution to the design of the tumor burden-guided dosing schedule at the University College London Cancer Institute. The corrected list of authors and their affiliations are shown above while the corrected contributions are shown below.
Footnotes
- Received May 27, 2026
- Accepted May 27, 2026
Correspondence
Contributions
EJ, JS, PL-S, WB, KSP, and CR designed the research and analyzed and interpreted the data. EJ, KSS, PS, ACL, MA, BDS, MRB, JHP, DJD, ET, DY, SC, KH, PB, MG, TM, KSP, and CR contributed vital new reagents or analytical tools and collected the data. JS and PL-S performed the statistical analysis. All authors performed the research and reviewed and approved the manuscript.
References
- Jabbour E, Karamjeet SS, Shaughnessy P. Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Haematologica. 2026; 111(6):1999-2010. https://doi.org/10.3324/haematol.2025.288587Google Scholar
Figures & Tables
Article Information
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.